{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:04:53Z","timestamp":1793228693126,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10147-025-02805-2","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T10:07:10Z","timestamp":1749722830000},"page":"1582-1592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Potassium-competitive acid blocker has more negative impacts on clinical outcomes in patients with non-small cell lung cancer treated with checkpoint inhibitors than those of proton pump inhibitors"],"prefix":"10.1007","volume":"30","author":[{"given":"Masaya","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Nakatsukasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Shibano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7696-2391","authenticated-orcid":false,"given":"Hiroyasu","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"2805_CR1","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1200\/JCO.23.02746","volume":"42","author":"IA Jaiyesimi","year":"2024","unstructured":"Jaiyesimi IA, Leighl NB, Ismaila N et al (2024) Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, version 2023.3. J Clin Oncol 42:e23\u2013e43. https:\/\/doi.org\/10.1200\/JCO.23.02746","journal-title":"J Clin Oncol"},{"key":"2805_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J et al (2023) Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34:358\u2013376. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.013","journal-title":"Ann Oncol"},{"key":"2805_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu T-E, Cobo M et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22:198\u2013211. https:\/\/doi.org\/10.1016\/S1470-2045(20)30641-0","journal-title":"Lancet Oncol"},{"key":"2805_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2217\/imt-2017-0121","volume":"10","author":"M Reck","year":"2018","unstructured":"Reck M (2018) Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer. Immunotherapy 10:93\u2013105. https:\/\/doi.org\/10.2217\/imt-2017-0121","journal-title":"Immunotherapy"},{"key":"2805_CR5","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"2805_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44276-023-00008-8","volume":"1","author":"C Hes","year":"2023","unstructured":"Hes C, Jagoe RT (2023) Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle. BJC Rep 1:1\u20139. https:\/\/doi.org\/10.1038\/s44276-023-00008-8","journal-title":"BJC Rep"},{"key":"2805_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12967-020-02231-0","volume":"18","author":"A Botticelli","year":"2020","unstructured":"Botticelli A, Vernocchi P, Marini F et al (2020) Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. J Transl Med 18:49. https:\/\/doi.org\/10.1186\/s12967-020-02231-0","journal-title":"J Transl Med"},{"key":"2805_CR8","doi-asserted-by":"publisher","first-page":"1257515","DOI":"10.3389\/fonc.2023.1257515","volume":"13","author":"H Zhang","year":"2023","unstructured":"Zhang H, Xu Z (2023) Gut-lung axis: role of the gut microbiota in non-small cell lung cancer immunotherapy. Front Oncol 13:1257515. https:\/\/doi.org\/10.3389\/fonc.2023.1257515","journal-title":"Front Oncol"},{"key":"2805_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/87551225231166531","volume":"39","author":"E St Onge","year":"2023","unstructured":"St Onge E, Phillips B (2023) Vonoprazan: a new potassium-competitive acid blocker. J Pharm Technol 39:139\u2013146. https:\/\/doi.org\/10.1177\/87551225231166531","journal-title":"J Pharm Technol"},{"key":"2805_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","volume":"11","author":"DS Strand","year":"2017","unstructured":"Strand DS, Kim D, Peura DA (2017) 25 years of proton pump inhibitors: a comprehensive review. Gut Liver 11:27\u201337. https:\/\/doi.org\/10.5009\/gnl15502","journal-title":"Gut Liver"},{"key":"2805_CR11","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1053\/j.gastro.2022.06.070","volume":"163","author":"N Nagata","year":"2022","unstructured":"Nagata N, Nishijima S, Miyoshi-Akiyama T et al (2022) Population-level metagenomics uncovers distinct effects of multiple medications on the human gut microbiome. Gastroenterology 163:1038\u20131052. https:\/\/doi.org\/10.1053\/j.gastro.2022.06.070","journal-title":"Gastroenterology"},{"key":"2805_CR12","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.3748\/wjg.v25.i22.2706","volume":"25","author":"G Bruno","year":"2019","unstructured":"Bruno G, Zaccari P, Rocco G et al (2019) Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified. World J Gastroenterol 25:2706\u20132719. https:\/\/doi.org\/10.3748\/wjg.v25.i22.2706","journal-title":"World J Gastroenterol"},{"key":"2805_CR13","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.3390\/cancers14061404","volume":"14","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, Cusmai A, Giovannelli F et al (2022) Impact of proton pump inhibitors and histamine-2-receptor antagonists on non-small cell lung cancer immunotherapy: a systematic review and meta-analysis. Cancers 14:1404. https:\/\/doi.org\/10.3390\/cancers14061404","journal-title":"Cancers"},{"key":"2805_CR14","doi-asserted-by":"publisher","first-page":"1070076","DOI":"10.3389\/fimmu.2023.1070076","volume":"14","author":"S Lopes","year":"2023","unstructured":"Lopes S, Pabst L, Dory A et al (2023) Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? a meta-analysis. Front Immunol 14:1070076. https:\/\/doi.org\/10.3389\/fimmu.2023.1070076","journal-title":"Front Immunol"},{"key":"2805_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/17474124.2021.1984878","volume":"16","author":"V Savarino","year":"2022","unstructured":"Savarino V, Antonioli L, Fornai M et al (2022) An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Rev Gastroenterol Hepatol 16:401\u2013410. https:\/\/doi.org\/10.1080\/17474124.2021.1984878","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2805_CR16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1136\/gutjnl-2016-313312","volume":"66","author":"T Otsuka","year":"2017","unstructured":"Otsuka T, Sugimoto M, Inoue R et al (2017) Influence of potassium-competitive acid blocker on the gut microbiome of Helicobacter pylori-negative healthy individuals. Gut 66:1723\u20131725. https:\/\/doi.org\/10.1136\/gutjnl-2016-313312","journal-title":"Gut"},{"key":"2805_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1124\/jpet.110.170274","volume":"335","author":"Y Hori","year":"2010","unstructured":"Hori Y, Imanishi A, Matsukawa J et al (2010) 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 335:231\u2013238. https:\/\/doi.org\/10.1124\/jpet.110.170274","journal-title":"J Pharmacol Exp Ther"},{"key":"2805_CR18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s12664-023-01384-2","volume":"42","author":"S Chandan","year":"2023","unstructured":"Chandan S, Deliwala S, Mohan BP et al (2023) Vonoprazan versus lansoprazole in erosive esophagitis - a systematic review and meta-analysis of randomized controlled trials. Indian J Gastroenterol 42:475\u2013484. https:\/\/doi.org\/10.1007\/s12664-023-01384-2","journal-title":"Indian J Gastroenterol"},{"key":"2805_CR19","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","volume":"29","author":"L Derosa","year":"2018","unstructured":"Derosa L, Hellmann MD, Spaziano M et al (2018) Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol 29:1437\u20131444. https:\/\/doi.org\/10.1093\/annonc\/mdy103","journal-title":"Ann Oncol"},{"key":"2805_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41416-021-01606-4","volume":"126","author":"AM Hopkins","year":"2022","unstructured":"Hopkins AM, Kichenadasse G, McKinnon RA et al (2022) Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Br J Cancer 126:42\u201347. https:\/\/doi.org\/10.1038\/s41416-021-01606-4","journal-title":"Br J Cancer"},{"key":"2805_CR21","doi-asserted-by":"publisher","first-page":"2081010","DOI":"10.1080\/2162402X.2022.2081010","volume":"11","author":"Y Tomita","year":"2022","unstructured":"Tomita Y, Goto Y, Sakata S et al (2022) Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors. Oncoimmunology 11:2081010. https:\/\/doi.org\/10.1080\/2162402X.2022.2081010","journal-title":"Oncoimmunology"},{"key":"2805_CR22","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1007\/s10147-024-02622-z","volume":"29","author":"H Nakatsukasa","year":"2024","unstructured":"Nakatsukasa H, Takahashi M, Shibano M et al (2024) Clinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor. Int J Clin Oncol 29:1840\u20131849. https:\/\/doi.org\/10.1007\/s10147-024-02622-z","journal-title":"Int J Clin Oncol"},{"key":"2805_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"2805_CR24","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1038\/s41598-024-53158-1","volume":"14","author":"K Iida","year":"2024","unstructured":"Iida K, Naiki T, Etani T et al (2024) Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma. Sci Rep 14:2520. https:\/\/doi.org\/10.1038\/s41598-024-53158-1","journal-title":"Sci Rep"},{"key":"2805_CR25","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","volume":"112","author":"N Chiba","year":"1997","unstructured":"Chiba N, De Gara CJ, Wilkinson JM et al (1997) Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 112:1798\u20131810. https:\/\/doi.org\/10.1053\/gast.1997.v112.pm9178669","journal-title":"Gastroenterology"},{"key":"2805_CR26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1053\/j.gastro.2009.09.063","volume":"138","author":"F-H Ng","year":"2010","unstructured":"Ng F-H, Wong S-Y, Lam K-F et al (2010) Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 138:82\u201388. https:\/\/doi.org\/10.1053\/j.gastro.2009.09.063","journal-title":"Gastroenterology"},{"key":"2805_CR27","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.14309\/ajg.0000000000001309","volume":"116","author":"K Watanabe","year":"2021","unstructured":"Watanabe K, Shimodaira Y, Takahashi S et al (2021) Potent acid suppression with vonoprazan vs proton pump inhibitors does not have higher association with Clostridioides difficile infection. Am J Gastroenterol 116:1632\u20131637. https:\/\/doi.org\/10.14309\/ajg.0000000000001309","journal-title":"Am J Gastroenterol"},{"key":"2805_CR28","doi-asserted-by":"publisher","first-page":"e076484","DOI":"10.1136\/bmj-2023-076484","volume":"385","author":"JE Kurlander","year":"2024","unstructured":"Kurlander JE, Laine L, Kim HM et al (2024) Impact of large scale, multicomponent intervention to reduce proton pump inhibitor overuse in integrated healthcare system: difference-in-difference study. BMJ 385:e076484. https:\/\/doi.org\/10.1136\/bmj-2023-076484","journal-title":"BMJ"},{"key":"2805_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00535-021-01769-0","volume":"56","author":"T Kamada","year":"2021","unstructured":"Kamada T, Satoh K, Itoh T et al (2021) Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J Gastroenterol 56:303\u2013322. https:\/\/doi.org\/10.1007\/s00535-021-01769-0","journal-title":"J Gastroenterol"},{"key":"2805_CR30","doi-asserted-by":"publisher","first-page":"e001361","DOI":"10.1136\/jitc-2020-001361","volume":"8","author":"A Cortellini","year":"2020","unstructured":"Cortellini A, Tucci M, Adamo V et al (2020) Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice. J Immunother Cancer 8:e001361. https:\/\/doi.org\/10.1136\/jitc-2020-001361","journal-title":"J Immunother Cancer"},{"key":"2805_CR31","doi-asserted-by":"publisher","first-page":"e2322915","DOI":"10.1001\/jamanetworkopen.2023.22915","volume":"6","author":"H Kawachi","year":"2023","unstructured":"Kawachi H, Yamada T, Tamiya M et al (2023) Concomitant proton pump inhibitor use with Pembrolizumab Monotherapy vs immune checkpoint inhibitor plus chemotherapy in patients with non-small cell lung cancer. JAMA Netw Open 6:e2322915. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.22915","journal-title":"JAMA Netw Open"},{"key":"2805_CR32","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1111\/bcp.15276","volume":"88","author":"N Wei","year":"2022","unstructured":"Wei N, Zheng B, Que W et al (2022) The association between proton pump inhibitor use and systemic anti-tumour therapy on survival outcomes in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. Br J Clin Pharmacol 88:3052\u20133063. https:\/\/doi.org\/10.1111\/bcp.15276","journal-title":"Br J Clin Pharmacol"},{"key":"2805_CR33","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1186\/1756-0500-7-605","volume":"7","author":"SA Sands","year":"2014","unstructured":"Sands SA, Tsau S, Yankee TM et al (2014) The effect of omeprazole on the development of experimental autoimmune encephalomyelitis in C57BL\/6J and SJL\/J mice. BMC Res Notes 7:605. https:\/\/doi.org\/10.1186\/1756-0500-7-605","journal-title":"BMC Res Notes"},{"key":"2805_CR34","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","volume":"65","author":"MA Jackson","year":"2016","unstructured":"Jackson MA, Goodrich JK, Maxan M-E et al (2016) Proton pump inhibitors alter the composition of the gut microbiota. Gut 65:749\u2013756. https:\/\/doi.org\/10.1136\/gutjnl-2015-310861","journal-title":"Gut"},{"key":"2805_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359:97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236","journal-title":"Science"},{"key":"2805_CR36","doi-asserted-by":"publisher","first-page":"12204","DOI":"10.1073\/pnas.0909122107","volume":"107","author":"JL Round","year":"2010","unstructured":"Round JL, Mazmanian SK (2010) Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A 107:12204\u201312209. https:\/\/doi.org\/10.1073\/pnas.0909122107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2805_CR37","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41598-020-80802-3","volume":"11","author":"T Kakiuchi","year":"2021","unstructured":"Kakiuchi T, Yamamoto K, Imamura I et al (2021) Gut microbiota changes related to Helicobacter pylori eradication with vonoprazan containing triple therapy among adolescents: a prospective multicenter study. Sci Rep 11:755. https:\/\/doi.org\/10.1038\/s41598-020-80802-3","journal-title":"Sci Rep"},{"key":"2805_CR38","doi-asserted-by":"publisher","first-page":"1040424","DOI":"10.3389\/fmolb.2022.1040424","volume":"9","author":"F Shoji","year":"2022","unstructured":"Shoji F, Yamaguchi M, Okamoto M et al (2022) Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer. Front Mol Biosci 9:1040424. https:\/\/doi.org\/10.3389\/fmolb.2022.1040424","journal-title":"Front Mol Biosci"},{"key":"2805_CR39","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2147\/JHC.S315696","volume":"8","author":"Y-C Shen","year":"2021","unstructured":"Shen Y-C, Lee P-C, Kuo Y-L et al (2021) An exploratory study for the association of gut microbiome with efficacy of immune checkpoint inhibitor in patients with hepatocellular carcinoma. J Hepatocell Carcinoma 8:809\u2013822. https:\/\/doi.org\/10.2147\/JHC.S315696","journal-title":"J Hepatocell Carcinoma"},{"key":"2805_CR40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.schres.2023.03.005","volume":"255","author":"Z Li","year":"2023","unstructured":"Li Z, Qing Y, Cui G et al (2023) Shotgun metagenomics reveals abnormal short-chain fatty acid-producing bacteria and glucose and lipid metabolism of the gut microbiota in patients with schizophrenia. Schizophr Res 255:59\u201366. https:\/\/doi.org\/10.1016\/j.schres.2023.03.005","journal-title":"Schizophr Res"},{"key":"2805_CR41","doi-asserted-by":"publisher","first-page":"e202895","DOI":"10.1001\/jamanetworkopen.2020.2895","volume":"3","author":"M Nomura","year":"2020","unstructured":"Nomura M, Nagatomo R, Doi K et al (2020) Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with Nivolumab or Pembrolizumab in patients with solid cancer tumors. JAMA Netw Open 3:e202895. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.2895","journal-title":"JAMA Netw Open"},{"key":"2805_CR42","doi-asserted-by":"publisher","first-page":"111619","DOI":"10.1016\/j.biopha.2021.111619","volume":"139","author":"R Mirzaei","year":"2021","unstructured":"Mirzaei R, Afaghi A, Babakhani S et al (2021) Role of microbiota-derived short-chain fatty acids in cancer development and prevention. Biomed Pharmacother 139:111619. https:\/\/doi.org\/10.1016\/j.biopha.2021.111619","journal-title":"Biomed Pharmacother"},{"key":"2805_CR43","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.3390\/cancers15133268","volume":"15","author":"I Robinson","year":"2023","unstructured":"Robinson I, Hochmair MJ, Schmidinger M et al (2023) Assessing the performance of a novel stool-based microbiome test that predicts response to first line immune checkpoint inhibitors in multiple cancer types. Cancers (Basel) 15:3268. https:\/\/doi.org\/10.3390\/cancers15133268","journal-title":"Cancers (Basel)"},{"key":"2805_CR44","doi-asserted-by":"publisher","first-page":"1434771","DOI":"10.3389\/fimmu.2024.1434771","volume":"15","author":"E Tabrizi","year":"2024","unstructured":"Tabrizi E, Pourteymour Fard Tabrizi F, Mahmoud Khaled G et al (2024) Unraveling the gut microbiome\u2019s contribution to pancreatic ductal adenocarcinoma: mechanistic insights and therapeutic perspectives. Front Immunol 15:1434771. https:\/\/doi.org\/10.3389\/fimmu.2024.1434771","journal-title":"Front Immunol"},{"key":"2805_CR45","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/1873-3468.14328","volume":"596","author":"AE Mohr","year":"2022","unstructured":"Mohr AE, Crawford M, Jasbi P et al (2022) Lipopolysaccharide and the gut microbiota: considering structural variation. FEBS Lett 596:849\u2013875. https:\/\/doi.org\/10.1002\/1873-3468.14328","journal-title":"FEBS Lett"},{"key":"2805_CR46","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2147\/CLEP.S49354","volume":"5","author":"F Hvid-Jensen","year":"2013","unstructured":"Hvid-Jensen F, Nielsen RB, Pedersen L et al (2013) Lifestyle factors among proton pump inhibitor users and nonusers: a cross-sectional study in a population-based setting. Clin Epidemiol 5:493\u2013499. https:\/\/doi.org\/10.2147\/CLEP.S49354","journal-title":"Clin Epidemiol"},{"key":"2805_CR47","doi-asserted-by":"publisher","first-page":"39640","DOI":"10.18632\/oncotarget.17387","volume":"8","author":"D Guo","year":"2017","unstructured":"Guo D, Wang C, Wang Q et al (2017) Pantoprazole blocks the JAK2\/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response. Oncotarget 8:39640\u201339648. https:\/\/doi.org\/10.18632\/oncotarget.17387","journal-title":"Oncotarget"},{"key":"2805_CR48","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/jcsm.12851","volume":"13","author":"Z Liu","year":"2022","unstructured":"Liu Z, Xiong J, Gao S et al (2022) Ameliorating cancer cachexia by inhibiting cancer cell release of Hsp70 and Hsp90 with omeprazole. J Cachexia Sarcopenia Muscle 13:636\u2013647. https:\/\/doi.org\/10.1002\/jcsm.12851","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2805_CR49","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/ijms21010323","volume":"21","author":"P Vinke","year":"2020","unstructured":"Vinke P, Wesselink E, van Orten-Luiten W et al (2020) The use of proton pump inhibitors may increase symptoms of muscle function loss in patients with chronic illnesses. Int J Mol Sci 21:323. https:\/\/doi.org\/10.3390\/ijms21010323","journal-title":"Int J Mol Sci"},{"key":"2805_CR50","doi-asserted-by":"publisher","first-page":"2442116","DOI":"10.1080\/2162402X.2024.2442116","volume":"14","author":"H Kawachi","year":"2025","unstructured":"Kawachi H, Yamada T, Tamiya M et al (2025) Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of \u226550% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy. Oncoimmunology 14:2442116. https:\/\/doi.org\/10.1080\/2162402X.2024.2442116","journal-title":"Oncoimmunology"},{"key":"2805_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-03848-7","author":"M Yal\u00e7\u0131ner","year":"2025","unstructured":"Yal\u00e7\u0131ner M, Yazgan SC, Mocan EE et al (2025) Impact of comorbidity on survival in cancer patients receiving immune checkpoint inhibitors. Clin Transl Oncol. https:\/\/doi.org\/10.1007\/s12094-025-03848-7","journal-title":"Clin Transl Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02805-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02805-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02805-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T07:37:15Z","timestamp":1753429035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02805-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2805"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02805-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Kaneda has received lecture fees from Chugai, MSD, Ono pharmaceutical, and Bristol-Myers Squibb. All other authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Human Subjects Review Committee of Osaka Metropolitan University (Approval no. 2023\u2013003). The need for informed consent was waived by the Human Subjects Review Committee at each hospital, and the participants were free to opt out if they no longer wished to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The need for informed consent was waived by the Human Subjects Review Committee of our hospital, and the participants were free to opt out if they no longer wished to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participation"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}